A Phase II/III, Randomized, Open Label, Controlled, Two Arm Study Comparing Overall Survival of AlloStim Combined With Cryoablation to a Physician's Choice Combined With Cryoablation in 3rd Line Treatment for Metastatic Colorectal Cancer
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 10 Aug 2016
At a glance
- Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Immunovative Therapies
- 10 Jun 2017 Biomarkers information updated
- 07 Aug 2016 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 07 Aug 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.